memo - Magazine of European Medical Oncology

, Volume 5, Issue 3, pp 174–177

Treating T-cell lymphoma: is there a light at the end of the tunnel?

  • Georg Hopfinger
  • Olaf Merkel
  • Thomas Melchardt
  • Richard Greil
short review

DOI: 10.1007/s12254-012-0013-4

Cite this article as:
Hopfinger, G., Merkel, O., Melchardt, T. et al. memo (2012) 5: 174. doi:10.1007/s12254-012-0013-4
  • 62 Downloads

Abstract

Treating peripheral T-cell lymphomas (PTCL) remains a clinical challenge harbouring an often aggressive course and furthermore, no standard therapy is established. In more detail, PTCL comprises a heterogeneous group of haematological tumours constituting less than 15 % of all non-Hodgkin’s lymphomas (NHLs) in adults in the western hemisphere. The following short review will provide an up-date based on data presented at ASH meeting 2011 in PTCL providing improved understanding of patho-mechanism and further development of more specific therapy options.

Keywords

PTCLPralatrexateRomidepsinBrentuximabAlisertibTransplantation

Copyright information

© Springer-Verlag Wien 2012

Authors and Affiliations

  • Georg Hopfinger
    • 1
  • Olaf Merkel
    • 1
  • Thomas Melchardt
    • 1
  • Richard Greil
    • 1
  1. 1.3rd Medical Department with Haematology, Medical Oncology, Haemostaseology, Rheumatology, Infectious Disease, Laboratory for Immunological and Molecular Cancer Research (LIMCR),Medical University Hospital, SalzburgSalzburgAustria